Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after In Vitro lymphocyte activation

Atefeh Yari 1, 4, Seyyed Abdolrahim Rezaee 2, Narges Valizadeh 3, Taraneh Rajaee 3, Seyyed Mohammad Jazayeri 4, Mojdeh Soltani 4, Mehdi Norouzi 4*

1 Microbiology and Virology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Inflammation and Inflammatory diseases Research Center, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
4 Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): HTLV-1 is the first human retrovirus that has been recognized and is associated with HAM/TSP and ATLL. Studies have shown that less than five percent of HTLV-1 infected carriers develop HAM/TSP or ATLL and about ninety-five percent remain asymptomatic. Therefore, the proviral load with Tax may affect cellular genes such as cytokines and oncogenes, as well as involve in pathogenicity.

Materials and Methods: Thirty HTLV-1 patients, thirty HTLV-1 healthy carriers, and MT-2 cell line were evaluated for HTLV-1 activity. PBMCs were isolated and activated using PMA and ionomycine. Real-time PCR and TaqMan methods were performed using specific primers and fluorescence probes for Tax expression and proviral load assessment. B2microglobulin (B2m) and albumin were used as controls in Tax expression and in proviral load, respectively.

Results: An insignificant increase in Tax expression was observed in rest PBMCs of HAM/TSP patients compared to healthy carriers. However, after lymphocyte activation there was a significant increase in Tax expression in HAM/TSP patients (P=0.042). The Proviral load in patients was significantly higher than in carriers. Moreover, there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load (R=0.37, P=0.012).

Conclusion: Although proviral load had been addressed as a valuable index for monitoring HTLV-1 infected subjects, the results of this study demonstrated that Tax expression in activated PBMCs along with proviral load assessment in HAM/TSP patients are a more reliable factor for determining the prognosis and monitoring healthy carriers and HAM/TSP patients.

Keywords: Gene expression, HAM/TSP, HTLV-1, Proviral load, Tax mRNA

Introduction

Human T-cell leukemia virus type-1 (HTLV-1) is an oncogenic human retrovirus that causes diseases with different clinical outcomes such as adult T-cell leukemia/lymphoma (1, 2), and inflammatory neurologic disease, mainly HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) (3, 4). Other autoimmune diseases including sjoegern’s syndrome, polymyositis, inflammatory arthritis and uveitis might be associated with HTLV-1 infection (5). Although the pathophysiology of these disorders has not been fully understood, it seems that immunovirological factors should play major roles.

HTLV-1 infects 10-20 million people all over the world (5). It is endemic in parts of the world including the Caribbean, parts of central Africa, Brazil, southern parts of the United States (6) and Northeast of Iran. Northeast of Iran is an endemic area for HTLV-1 and 2.1 percent of the residents of Mashhad, the largest city in northeast of Iran, are HTLV-1 carriers (7).

Studies have shown that less than five percent of HTLV-1 infected carriers develop HAM/TSP or ATLL while about 95 percent remain asymptomatic carriers (8). Patients who develop ATL are often infected in childhood with a clinical latency period of 20-60 years; in contrast, HAM/TSP patients have shorter clinical latency periods (9). Typically, patients with HAM/TSP have more HTLV-1 infected lymphocytes than asymptomatic carriers (10, 11).

*Corresponding author: Mehdi Norouzi, Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-21-88992660; email: mnorouzi@tums.ac.ir
A common reason for the pathogenesis of HTLV-1-associated diseases is T-cell growth activity and induction of T-cell proliferation by HTLV-1 transactivator (Tax) (12). Tax is a regulatory gene in HTLV-1 that is essential for cell transformation and replication. HTLV-1 transactivator encodes a phosphoprotein that increases HTLV-1 Long Terminal Repeat (LTR) transcription by activation of nuclear factors NF-κB. Tax does not bind directly to DNA fragments but activates other transcription factors such as NF-κB (13). It can activate many cell promoters such as promoters of IL-2, IL-2R, GM-CSF. Activation of these genes lead to continuous proliferation of HTLV-1 infected cells (14, 15). It has been reported that expression of Tax mRNA is increased after culturing peripheral blood mononuclear cells from HAM/TSP patients (16, 17).

HTLV-1 proviral load has been evaluated as predictor of HAM/TSP development. Some studies have shown that HTLV-1 proviral load is higher in HAM/TSP patients than in asymptomatic carriers (18, 19). Although proviral load has possibly an important role in the development of HAM/TSP, association between this factor and the disease remains unclear (23) and it seems this index is not able to differentiate HTLV-1 in latent phase. Therefore, it is estimated that assessment of proviral load along with Tax expression (an index of activity) should be a better indicator of developing HTLV-1 associated diseases. In this study, the HTLV-1 Tax mRNA expression and proviral loads in PBMCs of HAM/TSP patients and asymptomatic carriers were evaluated in two different conditions, base line and activated cells (20).

**Material and Methods**

**Subjects**

The study was approved by the Ethics Committee of Tehran University of Medical Sciences. Patients were admitted to the Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences (MUMS, Mashhad, Iran).

The patients had no history of previous treatment for HAM/TSP. Informed consents were obtained from the participants or their legal guardian at the first visit. The inclusion criterion was the definitive diagnosis of HAM/TSP according to the World Health Organization criteria (21-24). Thirty HAM/TSP patients, thirty HTLV-1 healthy carriers, and MT-2 cells were evaluated for HTLV-1 activity. Contamination of subjects with HTLV-1 were identified by serological methods and confirmed by PCR technique (7). MT-2 cell line is a human T-cell line that is infected with HTLV-1 (25, 26).

**Oligonucleotide designing and complementary DNA synthesis**

Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated blood samples by Ficoll density gradient (Sigma, Germany). A quantitative real-time PCR assay (TaqMan method) was carried out to measure Tax expression and proviral load of HTLV-1 in PBMCs using specific primers and a fluorogenic probe by a Rotor Gene Q real-time PCR machine. RNA was extracted from fresh PBMCs using viral RNA extraction Mini Kit (Qiagen, Germany) and complementary DNA (cDNA) was synthesized using Revert Aid™ First Strand cDNA Synthesis Kit (Fermentas, Germany). Table 1 shows the nucleotide sequence of primers and probes. The procedure for conventional PCR was as follows: 1 μl cDNA (100 ng/μl), 2.5 μl reaction buffer 10x, 0.5 μl dNTP (10 mM, GeNet Bio), 2 μl MgCl2 (25 mM, Fermentas), 0.5 μl each of primers (10 pM), 0.2 μl primer Taq DNA polymerase (5 U/μl, Fermentas), 12.8 μl distilled water. β2m was used as human housekeeping or reference gene in Tax expression measurement. The expression of this gene remains stable within PBMCs from samples (27).

**Cell culture**

After PBMCs isolation, the cells were washed with RPMI medium. Cells were then introduced into an enriched RPMI 1640 medium (containing 12% inactivated bovine serum albumin) in the presence of 1 mg /μl PMA (phorbol 12-myristate13-acetate), 25 ng/ml ionomycin, and incubated in 5% CO2, 95% humidity for 6 hr. Afterwards, samples were collected for RNA extraction. Moreover, a cell line (MT-2) culture with ionomycin and PMA was used as control.

**Real-time PCR HTLV-1 Proviral Load**

Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated blood samples by Ficoll density gradient (Sigma, Germany). DNA was extracted using Ge Net kit (Korea). To assess the

| HTLV-1 Tax: | The forward primer: (5096-5115); 5’-ATCCGTTAGAGCCTGCATAA-3’ |
| The reverse primer: (5180-5183, 7302-7312); 5’-CTTGGGAAATGGGCCCATG-3’ |
| The probe: (5123-5145); 5’-CATGCCCAAGACCCCGTGG-3’ |
| Beta 2- Microglobulin | The forward primer: TTGTCTTTCAGAAGCAGCTG |
| The reverse primer: CCACCTTACTATCATG |
| The probe: TCATCTGTTACACGGGAGCAT |
HTLV-1 proviral load, a real-time TaqMan PCR absolute method was carried out using HTLV-1 RG kit (Novin Gene, Iran) (28). Briefly, the HTLV-1 copy number was referred to the actual amount of cellular DNA by quantifying albumin gene as the reference gene. HTLV-1 and albumin DNA concentrations were calculated using two 5-point standard curves. The normalized value of the HTLV-1 proviral load was calculated as the ratio of (HTLV-1 DNA copies number /albumin DNA copies number/2) × 10^4 and expressed as the number of HTLV-1 proviruses per 10^8 PBMCs (7).

**Tax measurement**

After cDNA synthesis, serial dilutions of standards (5 for each gene) were applied to relatively quantify the mRNA copy number of each single gene. Two standard curve methods were used for target and reference genes quantification by a Rotor Gene Q real-time PCR machine (Qiagen, Germany). The Rotor Gene 6000 software was used to analyze the standards and the unknown mRNA copy numbers. The relative quantity of each mRNA was normalized to the relative quantity of β2m mRNA. Then the relative Tax expression levels for each sample were calculated by an equation: Tax Normalized Index = copy number of gene of interest (Tax)/copy number of reference gene (β2m). Then the fold change in expression for each group was calculated by the following equation: mean of Tax normalized index of test group/mean of Tax normalized index of healthy carriers.

**Results**

**Tax mRNA in HTLV-I infected subjects before stimulation of PBMCs**

The HTLV-1 Tax mRNA load was measured in PBMCs of HAM/TSP patients and asymptomatic carriers (ACs). The mean ± SEM of Tax mRNA load was 31.24±21.21 copies/ml in patients with HAM/TSP, while the value was 5.63±2.5 copies/ml in the ACs. An increase of 5.54-fold was observed in the patients group with HAM/TSP compared with the ACs, which was statistically insignificant (P=0.671, Mann Whitney). Figure 1. Difference between Tax gene expression before and after cells stimulation was statistically significant (P=0.000, Wilcoxon's test).

**Demographic results**

HAM/TSP patients and control group showed no significant difference in gender (P=0.292) Figure 2. The mean of age in carriers was 42.15, and in patients was 45.04. Analyzing the data showed there was no significant difference between two groups in respect of age (P=0.34). It needs to be noted that the HTLV-1-associated diseases such as HAM/TSP and HTLV-1 infection are more prevalent in women than in men in Iran (2). No correlation was found between Tax mRNA expression and gender (Spearman's rho test).

**Proviral load**

Real-time PCR was performed on DNA that was extracted from peripheral blood mononuclear cells as previously described. Men and women were significantly different in proviral load (P=0.009).

![Figure 1. mRNA Tax expression was assessed before and after activation with PMA and ionomycin.](image-url)
Proviral load in patients was significantly higher than in carriers \((P=0.004,\text{ Mann Whitney})\). The mean \(\pm\) SD proviral load in asymptomatic carriers was 460\(\pm\)153 copy/\(10^4\) PBMCs and in patients with HAM/TSP was 2052\(\pm\)579 copy/\(10^4\) PBMCs. Table 2. Results confirmed that proviral load in patients with HAM/TSP was 4.46 times higher than in asymptomatic carriers. To investigate the relationship between Tax gene expression and proviral load, Spearman’s rho test was used and there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load \((R=\%32, P=0.03)\).

**Table 2. Laboratory findings in HAM/TSP patients and carriers**

| Characteristics                        | Asymptomatic carriers | HAM/TSP patients | \(P\)-value |
|----------------------------------------|-----------------------|------------------|-------------|
| HTLV-1 Proviral load/\(10^4\) PBMCs     | 460\(\pm\)153         | 2052\(\pm\)579   | 0.004       |
| Tax expression copy/ml (before stimulation) | 5.63\(\pm\)2.5        | 31.24\(\pm\)21.21 | 0.671       |
| Tax expression copy/ml (after stimulation) | 99.72\(\pm\)27.37     | 2658\(\pm\)2005   | 0.042       |

**Figure 2.** The gender distribution in HAM/TSP patients and carriers

Provisional load in patients was significantly higher than in carriers \((P=0.004,\text{ Mann Whitney})\). The mean \(\pm\) SD proviral load in asymptomatic carriers was 460\(\pm\)153 copy/\(10^4\) PBMCs and in patients with HAM/TSP was 2052\(\pm\)579 copy/\(10^4\) PBMCs. Table 2. Results confirmed that proviral load in patients with HAM/TSP was 4.46 times higher than in asymptomatic carriers. To investigate the relationship between Tax gene expression and proviral load, Spearman’s rho test was used and there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load \((R=\%32, P=0.03)\).

**Discussion**

A nationwide survey by Iranian Blood Transfusion Organization (IBTO) in 1996 and other epidemiological studies demonstrated that Razavi and north Khorasan and Golestan provinces in northeast of Iran are endemic for HTLV-I infection. These studies suggested that the highest prevalence of the virus was observed in Razavi Khorasan and southeast of Golestan provinces mainly in Mashhad, Neyshabour and Kalalah (7, 29). Therefore the study of virus activities in Iran is an urgent priority.

In spite of the fact that HTLV-I and its associated diseases such as ATLL and HAM/TSP were studied for several years, the pathogenesis of HTLV-I-associated diseases and the interaction between virus, infected cells and the host immune system yet to be understood. Previous studies have provided evidence that T cell stimulation lead to viral protein expression in infected cells (30, 31). HTLV-I Tax is one of such protein that can induce pro-inflammatory cytokine production, mainly IL-2, GM-CSF and IFN-\(\gamma\), in CD4\(^+\) infected T cells (32). Pro-inflammatory cytokine production may affect on host immune responses results in forming inappropriate inflammatory reactions toward HAM/TSP (29). We have previously argued that the virological and host immune modulators might play the main roles in the pathophysiology of HAM/TSP (2).

This study showed that HTLV-I Tax mRNA expression dramatically increased in HAM/TSP patients compare to healthy carriers after in vitro PBMCs stimulation with PMA-ionomycine. However, Tax mRNA expression in HAM/TSP and healthy carriers in inactivated PBMCs did not show any differences.

This finding shows that HTLV-I infected T cells in HAM/TSP subjects maybe more sensitive to stimulatory signal and produces more Tax protein than healthy carriers. Moreover, these changes in Tax expression, as the immune-dominant antigen, of HTLV-I infected CD4\(^+\) cells make them more suitable to killing activities of specific CTLs too.

There are many controversial studies regarding the prognostic value of proviral load in healthy carriers or HAM/TSP patients. HTLV-I provirus load is generally higher in patients with HAM/TSP than ACs, however, there are ACs who have comparable HTLV-I proviral load with HAM/TSPs. Moreover, there have been conflicting reports on Tax expression and HAM/TSP progression. For instance, the results of a study indicated that Tax mRNA expression in HTLV-I-infected cells of HAM/TSP subjects after 12hr culture did not show any differences with ACs with high proviral load. Whereas others demonstrated that the Tax mRNA expression in HTLV-I infected cells was higher in patients with HAM/TSP than in ACs (33, 34).

Our study demonstrated that neither proviral load nor Tax in inactivated PBMCs are useful prognostic markers for monitoring of HTLV-I infected subjects. Tax expression may act as an index for viral activity and as an important index in predicting long-term status of HAM/TSP patients. The researchers still do not know why the small number of HTLV-I infected people develop associated diseases (35, 36).

The finding of the present study indicated that proviral load in HAM/TSP patients was statistically higher than asymptomatic carriers \((P=0.004)\). Although, Tax expression in inactivated PBMCs of HAM/TSP patients was more than asymptomatic carriers, it was not significant. Activated PBMCs of HAM/TSPs had 26.65 fold tax expressions than healthy carriers which was statistically meaningful. Therefore, if HTLV-I proviral load and Tax expression in activated PBMCs of HTLV-I infected
individuals taken into account, they may act as a new strong prognostic index for monitoring of healthy carriers and HAM/TSP patients.

However, there are some limitations for this study; it can be assessed at the same time the HTLV-1 HBZ expression as an important regulator of HTLV-1 replication. Moreover, assessment of these viral protein and host immune response such as T cell population or T cell transcription factor make the study very strong.

**Conclusion**

Proviral load and Tax production in infected subjects are clearly affect on development of HTLV-1 associated diseases (37, 38). However, it seems that in the presence of T cell stimulatory signals the amount of Tax expression from infected CD4+ cells is dramatically increase which may have two different effects, it makes these cells more susceptible to CTLs killing activities or induces pro-inflammatory cytokines production toward forming HTLV-1 associated diseases.

**Acknowledgment**

This research has been supported by Tehran University of Medical Sciences and Mashhad University of Medical Sciences research councils. We express our appreciation to the staff of inflammation research center in Mashhad University of Medical Sciences for great help.

**References**

1. Rezaee SA, Fazly Bazzaz BS. The significance of HTLV-1 in molecular oncology. Iran J Basic Med Sci 2013; 3:178.
2. Rafatpanah H, Rezaee A, Etemadi M, Farid Hosseini R, Khorram B, Afshar L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1 associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
3. Franchini G. Molecular mechanisms of human-T-cell leukemia/ lymphotropic virus type I infection. Blood 1995; 86:3619–3639.
4. Vakili R, Sabet F, Ahmadi Ghezeldasht S, Boostani R, Rafatpanah H, shamsian A, et al. Human T-lymphotropic virus type I (HTLV-I) proviral load and clinical features in Iranian HAM/TSP patients. Iran J Basic Med Sci 2013; 16:268-272.
5. Yakova M, Lezin A, Dantin F, Lagathu G, Olinso S, Jean-Baptiste G, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005; 2:4.
6. Manns A, Hisada M, LaGrenade L. Human-T-lymphotropic virus type I infection. Lancet 1999; 353:1951–1958.
7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, shamsian SK, Ahmadi S, Sohagandi L, Azarpazhooh MR, Rezaee SA, Farid R, Bazarbachi A. High prevalence of HTLV-1 infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011 Nov; 52:172-176.
8. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, et al. Correlation of human T-cell lymphotropic virus type I (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 T cells, and disease severity in– HTLV-1 associated myelopathy (HAM/TSP). blood 2002; 99:88 94.
9. Morteux F, Gabet AS, Watte E. Molecular and cellular aspects of HTLV-associated leukeno genesis in vivo. Leukemia 2003; 17:26–38.
10. Jacobson S, Zaninovic V, Mora C, Rodgers-Johnson P, Sheremata WA, Gibbs CJ Jr, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-1: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23:S196–200.
11. Jacobson S, Gupta A, Mattson D, Miglioli E, McFarlin DE. Immunological studies intoptical spastic paraparesis. Ann Neurol 1999; 27:149-156.
12. Nyborg JK, Dynan WS. Interaction of cellular proteins with the human T-cell leukaemia virus type I transcriptional control region. Purification of cellular proteins that bind the 21-base pair repeat elements. J Biol Chem 1990; 265:8230–8236.
13. Masuda ES, Imamura R, Amasaki Y, Arai, and K, Arai N. Signalling in to the T-cell nucleus: NFAT regulation. Cell Signal 1998; 10:599–611.
14. Hatanaka M, Kobayashi N, The pX Region of HTLV-I. Princess Takamatsu Symp 1984; 15:205-217.
15. Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci 2004; 9:2556-2576.
16. Pique C, Dokherel MC. In vivo production of proteins of HTLV type1: evidence from cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 2000; 16:1783–1786.
17. Poesj B, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415–7419.
18. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharf G, et al. Quantitative proviral DNA and antibody levels in the natural History of HTLV-1 infection. J Infect Dis 1999; 180:1497-1493.
19. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moriyto Y, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J Neurol Sci 1998; 4:586-593.
20. Iwanga M, Watanabe T, Utsunomiya T, Okayama M, Uchimaru K, Koh KR, et al. Human T-cell leukaemia virus type I (HTLV-I) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116:1211-1219.
21. Goncalves DU, Proietti FA, Barbosa Stancioli EF, Martins ML, Ribas JG, Martins Filho OA, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008; 7:98-107.
22. Izumo S. Neuropathology of HTLV-1-associated myelopathy (HAM/TSP). Neuropathology 2010; 30:480.
23. Rios Grassi MF, Olavarria VN, Kruschewsky RdA, Mascarenhas RE, Dourado I, Correia LCL, et al. Human T Cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83:1269-1274.
24. Matsura E, Yamano Y, Jacobson S. Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol 2010; 5:310-325.
25. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. TypeC virus particles in cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294:770-771.
26. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-7419.
27. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumbra A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004; 37:112-114, 116,118-119.
28. Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, et al. Quantification of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002; 102:37-51.
29. Kalavi Kh, Moradi A, Tabarraei A. Population based sero prevalence of HTLV-I infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci 2013; 16:225-228.
30. Lin HC, Dezzutti CS, Lal RB, Rabson AB. Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells. J Virol 1998; 72:6264-6270.
31. Lin HC, Hickey M, Hsu L, Medina D, Rabson AB. Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology 2005; 339:1-11.
32. Lin HC, Charlene S, Dezzutti, Renu B. LaLA, Rabson AB. Activation of Human T-Cell leukemia virus type 1 tax gene expression in chronically infected TCells. J Virol 1998; 7:6264-6270.
33. Furukawa Y, Saito M, Matsumoto W, Usuku K, Tanaka Y, Izumo S, et al. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type 1 (HTLV-I)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers. J Infect Dis 2003; 187:1116-1125.
34. Best I, Adaui V, Verdonck K, Gonzalez E, Tipismana M, Clark D, et al. Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 2006; 146:226–233.
35. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003; 308:1-12.
36. Bangham CR, Hall SE, Jeffery KJ, Vine AM, Witkover A, Nowak MA, et al. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci 1999; 354:691-700.
37. Akagi T, Ono H, Nyunoya H, Shimotohno K. Characterization of peripheral blood T-lymphocytes transduced with HTLV-1 Tax mutants with different trans-activating phenotype. Oncogene 1997; 14:2071-2078.
38. Grassmann R, Dengler C, Muller-Beckenstein I, Fleckenstein B, McGuire K, Doldhler MC, Sodroski JG, Haseltine WA. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a herpesvirus saimiri vector. Proc Natl Acad Sci USA 1989; 86:3351-3355.